Best practices for designing a robust genetic association study – looking for community tips

24 Eyl 17:33

When you start sketching a genetic association study, the first thing I do is a power calculation that ties together the expected effect size, allele frequency, phenotype prevalence, and the significance threshold you’ll use after multiple‑testing correction. Tools like *genpwr* or the *pwr* package in R let you plug in those numbers and get a ball‑park sample size; for a typical GWAS with a genome‑wide α ≈ 5 × 10⁻⁸ you’ll often need several thousand cases and controls unless you’re targeting a common variant with a very large odds ratio. If you have a limited budget, consider a two‑stage design: a discovery set for initial hits and a smaller replication cohort that you power specifically for those top SNPs. Population stratification is a classic source of false positives. I usually run a principal component analysis (PCA) on a set of LD‑pruned markers and include the top PCs as covariates in the association model. If you have admixed samples, tools like *ADMIXTURE* or *MOSAIC* can give you ancestry fractions that you can also adjust for. In addition, linear mixed models (LMMs) such as those implemented in *GEMMA*, *SAIGE*, or *BOLT‑LMM* handle both relatedness and subtle structure by modelling a genetic relationship matrix; they’re now the default for large biobank‑scale data. For the statistical model itself, stick with additive coding unless you have a strong biological reason to test dominant/recessive effects. Logistic regression works for case‑control phenotypes, while linear regression (or LMM) is appropriate for quantitative traits. Don’t forget to correct for the genomic inflation factor (λ) and, if needed, apply a genomic control adjustment. After you flag genome‑wide significant loci, set up a replication pipeline: genotype the lead SNPs (or a fine‑mapping panel) in an independent cohort, re‑run the same model, and check that the direction and magnitude of the effect are consistent. Meta‑analysis tools like *METAL* can combine discovery and replication results while accounting for heterogeneity. A few pitfalls I’ve seen repeatedly: (1) under‑estimating relatedness, which inflates type I error; (2) using imputed dosages without checking imputation quality (keep only SNPs with INFO > 0.8); (3) ignoring batch effects from different genotyping platforms—include a batch covariate or run a joint QC. As for resources, the *NHGRI‑EBI GWAS Catalog* is great for checking previously reported loci, and the *UK Biobank* pipelines (the “ukbtools” and “bgenie” scripts) give a solid, reproducible workflow from QC to association. Keep a version‑controlled analysis notebook (e.g., using *RMarkdown* or *Jupyter*) so you can trace every decision—this saves a lot of headaches when reviewers ask for details. Good luck with the study!

24 Eyl 18:23

When I set up a GWAS a few years back, the first thing I did was run a power calculation that explicitly incorporated the expected effect size, minor‑allele frequency, and the phenotype’s heritability. Tools like *Genetic Power Calculator* or the R package *pwr* give you a ballpark, but I always add a safety margin (≈10–15 %) because real‑world data rarely behave as nicely as the assumptions. That way you avoid the classic “under‑powered” trap that leads to a flood of false negatives. Population stratification was another pain point for me until I started using principal component analysis (PCA) on a set of ancestry‑informative markers. I usually compute the first 5–10 PCs and include them as covariates in the regression model; this simple step wipes out most spurious associations. If you have access to external reference panels (e.g., 1000 Genomes), projecting your samples onto those can help you spot hidden sub‑populations before you even run the association test. For the statistical model, I stick with linear mixed models (LMMs) when dealing with related individuals or subtle structure—software like *SAIGE* or *GEMMA* handles the random effects efficiently. If the phenotype is binary, a logistic LMM (or a Firth‑penalized logistic regression for rare variants) works well. I also run a quick “null model” check to make sure the genomic inflation factor (λ) stays around 1; anything higher flags residual confounding. Replication is where the workflow often breaks down. I always reserve a completely independent cohort (or at least a different recruitment site) for validation, and I run the same QC pipeline on both sets to keep things comparable. A useful tip: store the exact version numbers of reference genome, annotation files, and software in a *conda* environment or a Docker image—this eliminates “it works on my machine” mismatches when you hand the pipeline over to collaborators. Lastly, keep an eye on batch effects (plate, sequencing run, etc.) and correct them early with tools like *ComBat*; ignoring them is a common source of false positives that even a well‑powered study can’t rescue.